Table 1 Characterization of tumors used to derive model systems.

From: The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma

Cell Line

Tumor

Age (yrs)

Sex

Breed

Tumor location

Diagnosis

BRAF p.V595E status

BRAF p.V595E status (cell line)

Origin type

Co-B-658

270,858

10

Female spayed

Dachshund

Rostral maxilla

bOSCC

WT

n/a

PDX

Co–C-958

270,858

10

Female spayed

Dachshund

Rostral maxilla

bOSCC

WT

n/a

PDX

Co-F-1236

294,236

7

Male castrated

Alaskan malamute

Caudal mandible

cOSCC

WT

WT

PDX

Co-L-1236

294,236

7

Male castrated

Alaskan malamute

Caudal mandible

cOSCC

WT

WT

PDX

Co-G-1114

301,814

11

Male castrated

Miniature poodle

Caudal mandible

cOSCC

WT

WT

PDX

Co–N-1242

322,742

10

Female spayed

Yorkshire terrier

Caudal maxilla

pOSCC

WT

WT

Primary tumor

Co-I-913

301,313

4

Female spayed

Labradoodle

Caudal maxilla

pOSCC

V595E

V595E

PDX

Co-J-1220

303,520

6

Female spayed

Labrador retriever

Caudal maxilla

pOSCC

V595E

n/a

PDX

Co–O-172

324,672

2

Female spayed

Labrador retriever

Rostral maxilla

pOSCC

V595E

V595E

Primary tumor

  1. BRAF status is reported as wild type (WT), the specific mutant determined, or ‘n/a’ for cell lines found to be murine rather than canine. Diagnosis is the histological subtype, either basaloid (b), conventional (c), or papillary (p) OSCC.